Ozone Therapy in Patients With Diabetic Neuropathy

• Status: Not yet recruiting
• Trial end date: 2022-09-20
• Target enrollment: 0
• Participant gender: All

Summary

Diabetic neuropathies are the most prevalent chronic complications of diabetes mellitus. The early recognition and appropriate management of neuropathy in the patient with diabetes is important for patient's quality of life and life expectancy. Ozone is well known to have anti-inflammatory and analgesic effects through the inhibition of pro-inflammatory mediators; as well as. stimulation of anti-inflammatory mediators' release

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University

Criteria

Inclusion Criteria:

• Sixty adult diabetic patients (type II DM)

• clinically symptomatized painful neuropathy for six or more months.

Exclusion Criteria:

• Patients with other causes of neuropathy (e.g., vitamin B12 deficiency), hereditary neuropathies and entrapment neuropathies, overt neuropathy with foot ulcers and/or amputation, peripheral vascular diseases, vertebral pathologies (e.g., previous surgery, foraminal stenosis, spinal canal stenosis, and/or vertebral disc herniation)

• Patients with other medical conditions such as connective tissue diseases, thyroid disorders, significant renal or hepatic dysfunction, platelet dysfunction syndrome, critical thrombocytopenia, hemodynamic instability and septicemia

• local infection at the site of the procedure

• Consistent use of nonsteroidal anti-inflammatory drugs within the last two weeks

• Systemic corticosteroid administration or local injection at the suspected treatment site within the last month

• Recent fever or illness, hemoglobin level <10 g/dL, platelet count <105 _ 109/L, and/or tobacco use.